Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial ...

The FDA has accepted Novo’s application for a label extension for Rybelsus to reduce the risk of major adverse cardiovascular events (MACE) in adults with Type 2 diabetes who also have ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1.

Rybelsus (semaglutide) is an oral medication used in combination with exercise and a healthy diet to help treat type 2 diabetes. It’s best taken on an empty stomach but isn’t known to interact ...

Rybelsus (semaglutide) and Ozempic (semaglutide) are prescription drugs used to treat type 2 diabetes. Rybelsus comes as an oral tablet, while Ozempic comes as an injectable liquid solution. This ...

Novo already sells Rybelsus, an oral semaglutide treatment for diabetes patients, which comes in doses of 7 mg and 14 mg. The company reported sales of 23.3 billion Danish kroner ($3.4 billion ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

GLP-1 drugs include Ozempic and Rybelsus, both of which have been approved by the Food and Drug Administration to treat diabetes. They also include Saxenda and Wegovy, which the FDA approved for ...

The oral form, marketed as Rybelsus, has a much thinner body of evidence, Christopher Labos writes. Joel Saget AFP via Getty Images The publication last week of clinical practice guidelines for ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the ...